


## CLAIMS


- 1- Compounds with the following general formula I:



in which:

- the groups  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$ , which may be the same or different, each one of them consists in a hydrogen atom, an alkyl, aryl, aralkyl, acyl, sulfonyl or sugar group
- and the salts of those compounds with an acid that is acceptable in cosmetic terms, in the form of their optically pure isomer and any mixture of those isomers.
- except 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- except 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- and also except 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ )

- 2 - Compound according to claim 1 wherein said compound corresponds to the formula II (formula II = formula I in which  $R^1 = R^4 = -COCH_3$ ,  $R^2 = R^3 = CH_3$ ,  $R^5 = CH_3$ ) hereafter represented (2,9-diacetyloxy-1,10-dimethoxy-6-methyl-noraporphine):



according to claims 1 or 2 wherein said compounds are occurred from any source of supply, in particular by chemical synthesis, or by plant extraction.

- 4 - Compounds according to claim 3 wherein said compounds are obtained by plant extraction from *glaucium flavum*.
- 5- Cosmetic or dermatopharmaceutical compositions containing one or more compounds according to any of claims 1 to 4, alone or in association and a cosmetically acceptable carrier.
- 6- Cosmetic or dermatopharmaceutical compositions containing 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ), and 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ) and 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ), alone or in association, wherein said molecules are obtained either by synthesis, or by plant extraction, and a cosmetically acceptable carrier.
- 7- Cosmetic or dermatopharmaceutical compositions according to claims 5 or 6, wherein said compounds according to claims 1 to 4 or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ), and or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ) and or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ), are present at a concentration between 0.0001 (m/m) and 50% (m/m), preferably between 0.001 (m/m) and 20% (m/m).
- 8- Cosmetic or dermatopharmaceutical compositions according to any of claims 5 to 7, wherein said compounds according to claims 1 to 4 or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ), and or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ) and or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ), are used in the form of solution, dispersion,

emulsion, paste, or powder, individually or in the form of a premix, or are included individually or as a premix in vehicles constituted by carriers such as macro-, micro-, or nanocapsules, liposomes or chylomicrons, macro-, micro-, or nanoparticles or microsponges, or are adsorbed on organic polymer powders, talcs, bentonites, or other inorganic supports.

- 9- Cosmetic or dermopharmaceutical composition according to claims 5 to 8, wherein said compound are used individually or in the form of a premix in any formulation, namely emollient lotions, emollient milks, or emollient creams, milks and creams for care of the skin or hair, make-up-removing cleansing creams, lotions, or milks, foundation tint bases, sun-screen lotions, milks, or creams, artificial suntan lotions, milks, or creams, shaving creams and foams, aftershave lotions, shampoos, lipsticks, mascaras, or nail varnishes
- 10- Cosmetic or dermopharmaceutical composition according to claims 5 to 9, characterized in that it contains at least one and preferably several other ingredients commonly used in cosmetic practice in a cosmetically acceptable mixture, selected from among the following categories: organic or hydroglycolic solvents, fatty substances obtained by extraction or synthesis, ionic or non-ionic thickeners, softeners, opacifiers, stabilizers, emollients, silicones,  $\alpha$ -hydroxy acids, antifoaming agents, moisturizing agents, vitamins, perfumes, preservatives, sequestering agents, colouring agents, gel-forming and viscosity-increasing polymers, surfactants and emulsifiers, other water- or fat-soluble active principles, plant extracts, tissue extracts, marine extracts, sun filters, and antioxidants
- 11- Composition according to claim 10 containing a *glaucium flavum* extract.
- 12- Composition according to claim 11, wherein said *glaucium flavum* extract is incorporated in cosmetic or dermopharmaceutical preparations at concentrations varying between 0.01 and 100 % (p/p), preferentially between 0.1 and 10 % in weight of the final total composition.
- 13- Use of

- one or more compounds according to one of the claims 1 to 4,
- or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ )
- and or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ),
- and use of compositions described in any of above claims 5 to 12

like or for the preparation of cosmetic or dermatopharmaceutical compositions with the aim of decreasing pigmentation, in particular to lighten the complexion, attenuate senile lentigo, homogenize skin color, or lighten any pigmentation associated with melanin including that of the hair.

14- Use of

- one or more compounds according to one of the claims 1 to 4,
- or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ )
- or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ),
- and use of compositions described in any of above claims 5 to 12, like or for the preparation of cosmetic or dermatopharmaceutical compositions with the aim of an anti-age, anti-ageing, antiradicalaire, antioxydant treatment

15- Use of

- one or more compounds according to one of the claims 1 to 4,
- or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ )

- or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ),
- and use of compositions described in any of above claims 5 to 12 like or for the preparation of cosmetic or dermopharmaceutical compositions with the aim of a slimming, a reduction of the orange peel and/or overloads of the thighs and the hips, anti-cellulite treatment, skin firming, to refine contours of the face, more generally the lipogenesis inhibition.

16- Use of

- one or more compounds according to one of the claims 1 to 4,
- or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ )
- or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ),
- and use of described above compositions according to any of claims 5 to 12

in a form bound to or incorporated in or absorbed in or adsorbed on macro-, micro-, and nanoparticles, or macro-, micro-, and nanocapsules, for the treatment of textiles, natural or synthetic fibres, wools, and any materials that may be used for clothing or underwear for day or night intended to come into contact with the skin to exert their cosmetic effect via this skin/textile contact and to permit continuous topical delivery.

17- Use of

- one or more compounds according to one of the claims 1 to 4,
- or 2,9-dihydroxy-1,10-dimethoxy-6-methyl-noraporphine (formula I,  $R^1 = H$ ,  $R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ ),
- or 1,2,10-trimethoxy-9-hydroxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = CH_3$ ,  $R^4 = H$ ,  $R^5 = CH_3$ )

- and or 1,2,9,10-tetramethoxy-6-methyl-noraporphine (formula I,  $R^1 = R^2 = R^3 = R^4 = R^5 = CH_3$ ),
- and use of compositions described in any of above claims 5 to 12 for the preparation of medicinal products intended for skin care, particularly skin lightening and reducing its coloration under exposure to natural or artificial UV radiation. or in the objective of an anti-age, anti-ageing, antiradicalaire, antioxydant treatment, or in the objective of a slimming treatment, a reduction of the orange peel and/or overloads of the thighs and the hips, a anti-cellulite treatment, skin firming, more generally the lipogenesis inhibition